[go: up one dir, main page]

PE20241349A1 - Anticuerpos de union a cd3 - Google Patents

Anticuerpos de union a cd3

Info

Publication number
PE20241349A1
PE20241349A1 PE2024000894A PE2024000894A PE20241349A1 PE 20241349 A1 PE20241349 A1 PE 20241349A1 PE 2024000894 A PE2024000894 A PE 2024000894A PE 2024000894 A PE2024000894 A PE 2024000894A PE 20241349 A1 PE20241349 A1 PE 20241349A1
Authority
PE
Peru
Prior art keywords
seq
cdr2
cdr3
antigen
chain variable
Prior art date
Application number
PE2024000894A
Other languages
English (en)
Inventor
Nathan Trinklein
Schooten Wim Van
Shelley Force Aldred
Katherine Harris
Duy Pham
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20241349A1 publication Critical patent/PE20241349A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un anticuerpo multiespecifico caracterizado porque comprende: (i) un primer resto de union que tiene especificidad de union a CD3[deltaepsilon], que comprende: un dominio variable de cadena pesada que comprende: (A) una secuencia de CDR1 de SEQ ID NO: 29, una CDR2 de SEQ ID NO: 24, y una CDR3 de SEQ ID NO: 41; o (B) una CDR1 de SEQ ID NO: 34, una CDR2 de SEQ ID NO: 24 y una CDR3 de SEQ ID NO: 43; y un dominio variable de cadena liviana que comprende una secuencia de CDR1 de SEQ ID NO: 35, una CDR2 de SEQ ID NO: 38 y una CDR3 de SEQ ID NO: 45; y (ii) un segundo resto de union que tiene especificidad de union para un antigeno de diferenciacion hematopoyetica, un antigeno de diferenciacion de la superficie celular, un antigeno de senalizacion del factor de crecimiento, o un antigeno de matriz extracelular. Tambien se refiere a la produccion de dichos anticuerpos multiespecificos, una composicion farmaceutica que los comprende y su uso en el tratamiento del cancer.
PE2024000894A 2016-09-14 2017-06-20 Anticuerpos de union a cd3 PE20241349A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394360P 2016-09-14 2016-09-14
US201762491908P 2017-04-28 2017-04-28
PCT/US2017/038377 WO2018052503A1 (en) 2016-09-14 2017-06-20 Cd3 binding antibodies

Publications (1)

Publication Number Publication Date
PE20241349A1 true PE20241349A1 (es) 2024-07-03

Family

ID=61619675

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000520A PE20190976A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3
PE2024000894A PE20241349A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019000520A PE20190976A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3

Country Status (32)

Country Link
US (4) US11505606B2 (es)
EP (3) EP4050034B1 (es)
JP (7) JP7030109B2 (es)
KR (4) KR102507537B1 (es)
CN (3) CN109843325B (es)
AU (2) AU2017327723B2 (es)
BR (2) BR112019004873A2 (es)
CA (1) CA3036550A1 (es)
CL (4) CL2019000643A1 (es)
CO (1) CO2019003706A2 (es)
CR (3) CR20190198A (es)
DK (1) DK4050034T3 (es)
DO (3) DOP2019000059A (es)
EC (1) ECSP19026304A (es)
ES (1) ES2980623T3 (es)
FI (1) FI4050034T3 (es)
HR (1) HRP20240767T1 (es)
HU (1) HUE066651T2 (es)
IL (3) IL313895A (es)
LT (1) LT4050034T (es)
MX (4) MX2019002967A (es)
MY (1) MY200988A (es)
PE (2) PE20190976A1 (es)
PH (1) PH12019500545A1 (es)
PL (1) PL4050034T3 (es)
PT (1) PT4050034T (es)
RS (1) RS65595B1 (es)
SA (2) SA523442262B1 (es)
SI (1) SI4050034T1 (es)
UA (1) UA126384C2 (es)
WO (1) WO2018052503A1 (es)
ZA (1) ZA202203250B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811490XA (en) * 2016-06-21 2019-01-30 Teneobio Inc Cd3 binding antibodies
FI4050034T3 (fi) * 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
MX2019015563A (es) * 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CA3067584A1 (en) * 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
BR112020013086A2 (pt) * 2017-12-27 2020-12-08 Teneobio, Inc. Anticorpos específicos de heterodímero de cd3-delta/épsilon
JOP20200302A1 (ar) 2018-05-24 2020-11-23 Janssen Biotech Inc الأجسام المضادة لـ cd3 واستخداماتها
CA3106612A1 (en) 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with bcma specificity and uses thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
US12202898B2 (en) 2018-07-20 2025-01-21 TeneoTwo, Inc. Heavy chain antibodies binding to CD19
US10867104B2 (en) * 2018-08-31 2020-12-15 Taiwan Semiconductor Manufacturing Company Ltd. Isolation circuit between power domains
CN112955467A (zh) 2018-10-26 2021-06-11 特尼奥生物股份有限公司 与cd38结合的重链抗体
BR112021019334A2 (pt) 2019-04-05 2021-12-07 Teneobio Inc Anticorpos de cadeia pesada que se ligam ao psma
EA202290054A1 (ru) * 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
CN114341186A (zh) * 2019-07-30 2022-04-12 魁尔斯弗生物治疗股份有限公司 双特异性抗LRRC15和CD3ε抗体
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
PE20230431A1 (es) 2020-04-29 2023-03-08 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法
AU2021300179A1 (en) 2020-06-30 2023-02-02 Teneobio, Inc. Multi-specific antibodies binding to BCMA
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
US20240226162A9 (en) 2021-02-25 2024-07-11 Teneobio, Inc. Anti-psma antibodies and car-t structures
MX2023009882A (es) 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
AU2022255709A1 (en) 2021-04-06 2023-09-28 Teneobio, Inc. Anti-cd19 antibodies and car-t structures
BR112023021225A2 (pt) 2021-04-16 2023-12-19 Teneobio Inc Anticorpos anti-cd20 e estruturas t car
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
US20240376156A1 (en) * 2021-07-13 2024-11-14 University Of Washington Multiple de novo designed protein binding proteins
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
CA3228137A1 (en) 2021-08-09 2023-02-16 Harbour Biomed (Shanghai) Co., Ltd Cldn18.2-targeting antibody, bispecific antibody and use thereof
MX2024004550A (es) 2021-10-14 2024-04-29 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas.
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
AU2023356984A1 (en) 2022-10-05 2025-03-20 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
KR20240139569A (ko) * 2023-03-13 2024-09-23 머스트바이오 주식회사 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체
US20240398982A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
BR0007423A (pt) 1999-01-07 2002-01-22 Zymogenetics Inc Métodos para inibir a atividade de ztnf4 em um mamìfero e o acoplamento de receptor-ligando br43x2, taci ou bcma e para produzir um polipeptìdeo, molécula de polinucleotìdeo isolada, vetor de expressão, célula cultivada, e, polipeptìdeo isolado
TR200201063T2 (tr) 1999-08-17 2002-10-21 Biogen Inc. Bağışıklığı düzenleyici bir madde olan BAFF reseptörü (BCMA)
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
EP1280826B1 (en) 2000-05-12 2007-05-02 Amgen Inc. Polypeptides for inhibiting april-mediated b- and t-cell proliferation.
IL156690A0 (en) * 2000-12-29 2004-01-04 Savient Pharmaceuticals Inc Specific human antibodies for selective cancer therapy
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7919089B2 (en) 2003-05-31 2011-04-05 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for EpCAM
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
BRPI0417429A (pt) * 2003-12-10 2007-04-03 Medarex Inc anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DK1753783T3 (en) 2004-06-03 2014-11-17 Novlmmune Sa Anti-CD3 antibodies, and methods of use thereof
KR101422286B1 (ko) 2004-07-22 2014-07-23 에라스무스 유니버시티 메디컬 센터 로테르담 결합 분자
SG170006A1 (en) 2005-02-18 2011-04-29 Medarex Inc Monoclonal antibodies against cd30 lacking fucosyl residues
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CN101217979A (zh) 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP1957099B1 (en) 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
EA200801171A1 (ru) 2005-12-06 2008-12-30 Домантис Лимитед Биспецифичные лиганды, обладающие специфичностью связывания с поверхностными клеточными мишенями, и способы их применения
EP2010566B2 (en) 2006-04-05 2017-07-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
US7862813B2 (en) 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
CA2662350A1 (en) * 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
CN101675077B (zh) 2007-04-03 2013-09-04 安进研发（慕尼黑）股份有限公司 跨种特异性的双特异性结合剂
SG195609A1 (en) 2007-04-03 2013-12-30 Amgen Res Munich Gmbh Cross-species-specific binding domain
CA2683370C (en) 2007-04-03 2022-12-13 Micromet Ag Cross-species-specific binding domain
DK2152880T3 (da) 2007-06-01 2011-11-28 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer
JP5739326B2 (ja) 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
EP4180458A1 (en) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
MX338038B (es) 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
HRP20160857T4 (hr) 2008-10-01 2022-12-09 Amgen Research (Munich) Gmbh Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
NZ612647A (en) 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
PT2501817E (pt) * 2010-02-08 2015-11-04 Regeneron Pharma Rato de cadeia leve comum
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
EP2683735A1 (en) * 2011-03-10 2014-01-15 HCO Antibody, Inc. Bispecific three-chain antibody-like molecules
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
MY177970A (en) 2011-05-27 2020-09-28 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013158856A2 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10002206B2 (en) 2012-10-26 2018-06-19 Saturn Licensing Llc Information processing device and information processing method
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
LT2931030T (lt) 2012-12-14 2020-11-10 Open Monoclonal Technology, Inc. Polinukleotidai, koduojantys graužikų antikūnus su žmogaus idiotipais, ir juos apimantys gyvūnai
EP2762496A1 (en) * 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
ES2829499T3 (es) 2013-02-05 2021-06-01 Engmab Sarl Método para la selección de anticuerpos contra BCMA
SG11201603088RA (en) 2013-10-31 2016-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2015149077A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172235A2 (en) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
ES2701061T5 (es) 2014-10-22 2022-05-09 Crescendo Biologics Ltd Ratones transgénicos
CN107207609B (zh) * 2014-11-20 2022-07-19 豪夫迈·罗氏有限公司 共同轻链和使用方法
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3640262A1 (en) 2014-12-12 2020-04-22 Bluebird Bio, Inc. Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
EP3056512A1 (en) * 2015-02-10 2016-08-17 Medizinische Universität Wien Antibody construct
CN106211261B (zh) 2015-04-10 2020-10-16 中兴通讯股份有限公司 信息处理方法及通信节点
UA124143C2 (uk) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MA53750A (fr) 2015-08-17 2021-09-15 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
CN108884162A (zh) 2015-11-10 2018-11-23 汉堡-埃普多夫大学医学中心 针对cd38的抗原结合多肽
SG11201811490XA (en) 2016-06-21 2019-01-30 Teneobio Inc Cd3 binding antibodies
EP3503722A1 (en) 2016-08-24 2019-07-03 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
FI4050034T3 (fi) * 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
MX2019015563A (es) 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN111094345B (zh) 2017-06-30 2023-10-27 美国卫生和人力服务部 具有人结构域的抗b细胞成熟抗原嵌合抗原受体
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
BR112020013086A2 (pt) 2017-12-27 2020-12-08 Teneobio, Inc. Anticorpos específicos de heterodímero de cd3-delta/épsilon
CN112203661A (zh) * 2018-05-24 2021-01-08 艾雅拉制药公司 包含双氟烷基-1,4-苯并二氮杂*酮化合物与免疫治疗剂的组合物和其使用方法
US12202898B2 (en) 2018-07-20 2025-01-21 TeneoTwo, Inc. Heavy chain antibodies binding to CD19
BR112021004680A2 (pt) 2018-09-21 2021-08-31 Teneobio, Inc. Métodos para purificar anticorpos multiespecíficos heterodiméricos
CN112955467A (zh) 2018-10-26 2021-06-11 特尼奥生物股份有限公司 与cd38结合的重链抗体
BR112021019334A2 (pt) 2019-04-05 2021-12-07 Teneobio Inc Anticorpos de cadeia pesada que se ligam ao psma
EA202290054A1 (ru) * 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
PE20230431A1 (es) 2020-04-29 2023-03-08 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
US20220235380A1 (en) * 2021-01-26 2022-07-28 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
MX2024004550A (es) * 2021-10-14 2024-04-29 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas.

Also Published As

Publication number Publication date
LT4050034T (lt) 2024-06-10
RU2019111037A (ru) 2020-10-15
FI4050034T3 (fi) 2024-06-10
SI4050034T1 (sl) 2024-07-31
JP2022061992A (ja) 2022-04-19
ES2980623T3 (es) 2024-10-02
IL313895A (en) 2024-08-01
RU2019111037A3 (es) 2020-11-26
CN109843325B (zh) 2023-10-03
JP2019536430A (ja) 2019-12-19
IL290517B1 (en) 2024-08-01
CL2022003769A1 (es) 2023-07-21
JP2024023251A (ja) 2024-02-21
CR20190198A (es) 2019-10-11
MX2022002018A (es) 2022-03-11
EP4050034B1 (en) 2024-05-08
CA3036550A1 (en) 2018-03-22
DK4050034T3 (da) 2024-06-03
MY200988A (en) 2024-01-27
DOP2022000233A (es) 2022-11-30
CN114395048B (zh) 2025-01-28
PL4050034T3 (pl) 2024-07-22
DOP2023000165A (es) 2023-10-15
CN109843325A (zh) 2019-06-04
AU2022201278A1 (en) 2022-03-17
JP7521729B2 (ja) 2024-07-24
EP4417263A2 (en) 2024-08-21
KR102505681B1 (ko) 2023-03-06
PH12019500545A1 (en) 2019-07-29
EP4050034A1 (en) 2022-08-31
US20220025047A1 (en) 2022-01-27
IL290517A (en) 2022-04-01
CN117603353A (zh) 2024-02-27
CL2019000643A1 (es) 2019-08-09
AU2017327723A1 (en) 2019-05-02
IL265321B1 (en) 2023-09-01
CL2021003290A1 (es) 2022-07-15
KR102507537B1 (ko) 2023-03-08
US20200048348A1 (en) 2020-02-13
BR122022002481A8 (pt) 2023-02-07
CL2021003289A1 (es) 2022-07-15
AU2017327723B2 (en) 2022-11-17
KR102507537B9 (ko) 2025-01-10
CR20220578A (es) 2023-01-17
US20230272075A1 (en) 2023-08-31
PE20190976A1 (es) 2019-07-09
RS65595B1 (sr) 2024-06-28
IL265321B2 (en) 2024-01-01
JP2022061993A (ja) 2022-04-19
EP3512549A1 (en) 2019-07-24
ZA202203250B (en) 2022-05-25
MX2019002967A (es) 2019-07-04
EP3512549A4 (en) 2020-06-17
PT4050034T (pt) 2024-05-27
IL290517B2 (en) 2024-12-01
JP2024023252A (ja) 2024-02-21
US11505606B2 (en) 2022-11-22
RU2022103374A (ru) 2022-03-02
CO2019003706A2 (es) 2019-06-28
KR20230035706A (ko) 2023-03-14
KR20240044520A (ko) 2024-04-04
MX2024011615A (es) 2024-09-30
AU2022201278B2 (en) 2022-04-21
UA126384C2 (uk) 2022-09-28
BR122022002481A2 (es) 2019-06-11
BR112019004873A2 (pt) 2019-06-11
MX2024011616A (es) 2024-09-30
SA523442262B1 (ar) 2024-05-19
JP2024153676A (ja) 2024-10-29
US20230082151A1 (en) 2023-03-16
JP7521728B2 (ja) 2024-07-24
ECSP19026304A (es) 2019-06-30
CR20220408A (es) 2022-10-20
JP7321303B2 (ja) 2023-08-04
KR20220032640A (ko) 2022-03-15
HRP20240767T1 (hr) 2024-09-13
JP7431868B2 (ja) 2024-02-15
IL265321A (en) 2019-05-30
DOP2019000059A (es) 2019-06-16
JP2023156342A (ja) 2023-10-24
KR20190052048A (ko) 2019-05-15
WO2018052503A1 (en) 2018-03-22
JP7030109B2 (ja) 2022-03-04
CN114395048A (zh) 2022-04-26
EP4417263A3 (en) 2024-11-20
US11421027B2 (en) 2022-08-23
SA522431672B1 (ar) 2023-11-12
HUE066651T2 (hu) 2024-08-28

Similar Documents

Publication Publication Date Title
PE20241349A1 (es) Anticuerpos de union a cd3
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
AR117727A1 (es) Anticuerpos que se unen a cd3
MX2024010239A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
MX395074B (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CL2018000263A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3.
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20131209A1 (es) Anticuerpos anti-fap
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
AR084315A1 (es) Anticuerpos anti-notch1
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso